AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35764103 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-30% SF6 gas tamponade (Group A)
Number of subjects: 144
Study 35764103 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (BSS) (Group B)
Number of subjects: 144
Study 35764103 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 144
Study 34430405 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized psychological intervention
Number of subjects: 78
Study 34430405 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing care
Number of subjects: 78
Study 34430405 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study 32737104 — intervention group
Group type: COMPARATOR
Intervention: PsA (model0)
Number of subjects: 5748
Study 32737104 — intervention group
Group type: COMPARATOR
Intervention: PsA (model1)
Number of subjects: 5748
Study 32737104 — intervention group
Group type: COMPARATOR
Intervention: PsA (model2)
Number of subjects: 5748
Study 32737104 — intervention group
Group type: COMPARATOR
Intervention: Psoriasis without arthritis
Number of subjects: 5748
Study 32737104 — intervention group
Group type: COMPARATOR
Intervention: Genetically determined psoriasis/PsA
Number of subjects: 5748
Study 32737104 — intervention group
Group type: COMPARATOR
Intervention: MR analysis
Number of subjects: 5748
Study 35484990 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP‐choline (5 mg/kg in 0.1 mL/kg 0.9% saline, IV; n=9)
Number of subjects: 17
Study 35484990 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (0.1 mL/kg sterile 0.9% saline, IV; n=8)
Number of subjects: 17
Study 34435426 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder MRA
Number of subjects: 200
Study 32597287 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar vibration stimuli for 2 minutes
Number of subjects: 16
Study 32597287 — intervention group
Group type: COMPARATOR
Intervention: Sham interventions
Number of subjects: 16
Study 35329361 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Fat Chocolate Milk (LFCM)
Number of subjects: 7
Study 35329361 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 7
Study 35803302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory strategy to prevent atelectasis (VESPA) with endotracheal intubation, recruitment maneuver, FIO2 titration (< 100%), and PEEP of 8 to 10 cm H2O.
Number of subjects: 76
Study 35803302 — intervention group
Group type: COMPARATOR
Intervention: Standard ventilation (laryngeal mask airway, 100% FIO2, zero PEEP).
Number of subjects: 76
Study 35803302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory strategy to prevent atelectasis (VESPA).
Number of subjects: 76
Study 35803302 — intervention group
Group type: COMPARATOR
Intervention: Standard ventilation (control group).
Number of subjects: 76
Study 34046861 — intervention group
Group type: EXPERIMENTAL
Intervention: NOACs (apixaban, rivaroxaban, dabigatran)
Number of subjects: 29
Study 34046861 — intervention group
Group type: EXPERIMENTAL
Intervention: NOACs
Number of subjects: 29
Study 34046861 — intervention group
Group type: COMPARATOR
Intervention: VKAs (age-matched and sex-matched controls)
Number of subjects: 29
Study 34046861 — intervention group
Group type: COMPARATOR
Intervention: VKAs (historical controls)
Number of subjects: 29
Study 32950763 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (beta-adrenergic receptor antagonist)
Number of subjects: 24
Study 32950763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32950763 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary cortisol levels
Number of subjects: 24
Study 36184697 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 24 mg
Number of subjects: 72
Study 36184697 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab 0.8 mg/kg
Number of subjects: 72
Study 36184697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 33949213 — intervention group
Group type: EXPERIMENTAL
Intervention: High-altitude (HA) exposure
Number of subjects: 8
Study 32089455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus FOLFOX-4 (Arm A)
Number of subjects: 132
Study 32089455 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus XELOX-2 (Arm B)
Number of subjects: 132
Study 34520429 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery alone (S)
Number of subjects: 367
Study 34520429 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy plus surgery (C+S)
Number of subjects: 367
Study 33487014 — intervention group
Group type: EXPERIMENTAL
Intervention: P. cinnamomi, P. pini, and P. plurivora
Number of subjects: 6
Study 33487014 — intervention group
Group type: EXPERIMENTAL
Intervention: P. pseudocryptogea
Number of subjects: 6
Study 33487014 — intervention group
Group type: EXPERIMENTAL
Intervention: P. cambivora
Number of subjects: 6
Study 33487014 — intervention group
Group type: EXPERIMENTAL
Intervention: P. plurivora (one isolate)
Number of subjects: 6
Study 33192057 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based physical activity coaching in addition to usual care
Number of subjects: 74
Study 33192057 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 74
Study 616277889 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (5 g/day; Placebo)
Number of subjects: 30
Study 616277889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg/day; Pio)
Number of subjects: 30
Study 616277889 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA+DHA concentrate (5 g/day, containing 2.8 g EPA+DHA; Omega-3)
Number of subjects: 30
Study 616277889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone and EPA+DHA concentrate (PioOMEGA-3)
Number of subjects: 30
Study 35972773 — intervention group
Group type: EXPERIMENTAL
Intervention: Male synthetic sling
Number of subjects: 380
Study 35972773 — intervention group
Group type: COMPARATOR
Intervention: Artificial urinary sphincter
Number of subjects: 380
Study 32276071 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g/kg alcohol intake
Number of subjects: 65
Study 32276071 — intervention group
Group type: COMPARATOR
Intervention: 0.02 g/kg alcohol intake (placebo)
Number of subjects: 65
Study 32276071 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations related to alcohol intake
Number of subjects: 65
Study 36451343 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab
Number of subjects: 127
Study 36451343 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 127
Study 36451343 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab (in patients with BM)
Number of subjects: 127
Study 36451343 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib (in patients with BM)
Number of subjects: 127
Study 33973233 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab + Bendamustine
Number of subjects: 346
Study 33973233 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine
Number of subjects: 346
Study 34353737 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Resistance (IR)
Number of subjects: 23
Study 34353737 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte membrane fatty acid compositions
Number of subjects: 23
Study 33788436 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (lifting‐thrusting reinforcing and uniform reducing‐reinforcing methods) applied to specific acupuncture points for 20 min once daily for 3 months.
Number of subjects: 30
Study 33788436 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication group taking Tripterygium Wilfordii Polyglycoside tablets (one tablet per time, 3 times a day) for 3 months.
Number of subjects: 30
Study 33788436 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture group vs Medication group
Number of subjects: 30
Study 32569494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular examination (external and slit) in ICU and COVID wards
Number of subjects: 142
Study 32569494 — intervention group
Group type: COMPARATOR
Intervention: Patients with ocular manifestations
Number of subjects: 142
Study 32569494 — intervention group
Group type: COMPARATOR
Intervention: Patients admitted to ICU
Number of subjects: 142
Study 32569494 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival hyperemia
Number of subjects: 142
Study 32569494 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemosis
Number of subjects: 142
Study 35771607 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention arm (exercise intervention with Fitbit One)
Number of subjects: 75
Study 35771607 — intervention group
Group type: COMPARATOR
Intervention: Light intervention arm (minimal exercise intervention with Fitbit One)
Number of subjects: 75
Study 35771607 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention arm
Number of subjects: 75
Study 35771607 — intervention group
Group type: COMPARATOR
Intervention: Light intervention arm
Number of subjects: 75
Study 34344019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 24
Study 34344019 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 24
Study 36209209 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) with glucose meter, blood test-strips, log-book, waste management box, and training on SMBG in addition to usual care.
Number of subjects: 80
Study 36209209 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 80
Study 36209209 — intervention group
Group type: COMPARATOR
Intervention: Usual care (routine monthly medical consultation and health education)
Number of subjects: 80
Study 33129680 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational stocking (27–29 mmHg pressure at the medial supramalleolar level, no compression in foot and heel)
Number of subjects: 47
Study 33129680 — intervention group
Group type: COMPARATOR
Intervention: Standard stocking (23–32 mmHg)
Number of subjects: 47
Study 33213125 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement containing 120 mg HA, 240 mg CS, and 300 mg K once a day for 4 weeks
Number of subjects: 30
Study 33213125 — intervention group
Group type: COMPARATOR
Intervention: Control group (arthrocentesis only)
Number of subjects: 30
Study 35345251 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 0
Study 35345251 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0
Study 33476387 — intervention group
Group type: EXPERIMENTAL
Intervention: remdesivir
Number of subjects: 19
Study 33476387 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 33783257 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma‐Focused Cognitive Behavioral Therapy (TF‐CBT)
Number of subjects: 99
Study 34210340 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrrolate/formoterol fumarate (BGF) 320/18/9.6 μg
Number of subjects: 23
Study 34210340 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate/formoterol fumarate (GFF) 18/9.6 μg
Number of subjects: 23
Study 35431231 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric EC
Number of subjects: 342
Study 35431231 — intervention group
Group type: EXPERIMENTAL
Intervention: Nongeriatric EC
Number of subjects: 342
Study 32729789 — intervention group
Group type: COMPARATOR
Intervention: Inulin (control)
Number of subjects: 19
Study 32729789 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMITOR® Soluble Corn Fiber 70 (SCF70)
Number of subjects: 19
Study 32729789 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMITOR® Soluble Corn Fiber 85B (SCF85B)
Number of subjects: 19
Study 32729789 — intervention group
Group type: EXPERIMENTAL
Intervention: SCF70 and SCF85B
Number of subjects: 19
Study 36121651 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy (360 mg Q3W or 240 mg Q2W plus XELOX or FOLFOX)
Number of subjects: 208
Study 33523728 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO percutaneous coronary intervention
Number of subjects: 0
Study 33523728 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Total Occlusion Academic Research Consortium
Number of subjects: 0
Study 35553827 — intervention group
Group type: EXPERIMENTAL
Intervention: EX+MitoQ (20 mg/day, oral)
Number of subjects: 32
Study 35553827 — intervention group
Group type: EXPERIMENTAL
Intervention: EX+MitoQ
Number of subjects: 32
Study 35553827 — intervention group
Group type: COMPARATOR
Intervention: EX
Number of subjects: 32
Study 35553827 — intervention group
Group type: EXPERIMENTAL
Intervention: MitoQ
Number of subjects: 32
Study 33269951 — intervention group
Group type: EXPERIMENTAL
Intervention: erenumab 70 mg
Number of subjects: 358
Study 33269951 — intervention group
Group type: EXPERIMENTAL
Intervention: erenumab 140 mg
Number of subjects: 358
Study 33269951 — intervention group
Group type: EXPERIMENTAL
Intervention: erenumab (64 weeks treatment)
Number of subjects: 358
Study 33269951 — intervention group
Group type: EXPERIMENTAL
Intervention: erenumab (delayed reversion)
Number of subjects: 358
Study 33966283 — intervention group
Group type: EXPERIMENTAL
Intervention: BACtrack Mobile Pro
Number of subjects: 20
Study 33966283 — intervention group
Group type: EXPERIMENTAL
Intervention: BACtrack Vio
Number of subjects: 20
Study 33966283 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohoot
Number of subjects: 20
Study 33966283 — intervention group
Group type: EXPERIMENTAL
Intervention: Floome
Number of subjects: 20
Study 33966283 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinkmate
Number of subjects: 20
Study 33966283 — intervention group
Group type: EXPERIMENTAL
Intervention: Evoc
Number of subjects: 20
Study 33966283 — intervention group
Group type: COMPARATOR
Intervention: Police-grade device (Intoxilyzer 240)
Number of subjects: 20
Study 34426994 — intervention group
Group type: EXPERIMENTAL
Intervention: Rethink My Drink (internet-delivered intervention)
Number of subjects: 842
Study 34426994 — intervention group
Group type: COMPARATOR
Intervention: Alcohol: The Facts (online patient information booklet)
Number of subjects: 842
Study 32798723 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (10 mL) added to 1000 mL saline solution
Number of subjects: 100
Study 32798723 — intervention group
Group type: COMPARATOR
Intervention: Saline alone (1000 mL)
Number of subjects: 100
Study 35232299 — intervention group
Group type: EXPERIMENTAL
Intervention: Online sexual and urinary rehabilitation curriculum tailored for this population
Number of subjects: 401
Study 35232299 — intervention group
Group type: EXPERIMENTAL
Intervention: Online recruitment strategies
Number of subjects: 401
Study 35232299 — intervention group
Group type: EXPERIMENTAL
Intervention: Online sex/dating application
Number of subjects: 401
Study 35232299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer support site
Number of subjects: 401
Study 35232299 — intervention group
Group type: EXPERIMENTAL
Intervention: Social networking site
Number of subjects: 401
Study 35232299 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based recruitment
Number of subjects: 401
Study 35232299 — intervention group
Group type: EXPERIMENTAL
Intervention: Online recruitment methods
Number of subjects: 401
Study 32913166 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT) applied post-surgery for 7 days
Number of subjects: 60
Study 32913166 — intervention group
Group type: COMPARATOR
Intervention: Control group without KT application
Number of subjects: 60
Study 35915267 — intervention group
Group type: EXPERIMENTAL
Intervention: NARC-15 tablets oxycodone-acetaminophen 5/325 mg (A-OXY)
Number of subjects: 104
Study 35915267 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID-15 tablets ibuprofen (IBU) 600 mg
Number of subjects: 104
Study 35915267 — intervention group
Group type: EXPERIMENTAL
Intervention: CNSL-15 tablets A-OXY, 15 tablets IBU, and preoperative counseling
Number of subjects: 104
Study 35915267 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 104
Study 33524440 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) intervention with a self-selected daily 10-hour window between 6 AM and 8 PM
Number of subjects: 17
Study 33524440 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) intervention
Number of subjects: 17
Study 32221736 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ERAS® group
Number of subjects: 487
Study 32221736 — intervention group
Group type: COMPARATOR
Intervention: Pre-ERAS® group
Number of subjects: 487
Study 32221736 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient subgroup
Number of subjects: 487
Study 32221736 — intervention group
Group type: COMPARATOR
Intervention: Inpatient subgroup
Number of subjects: 487
Study 36360738 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided ACT-based online intervention
Number of subjects: 89
Study 36360738 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual
Number of subjects: 89
Study 35467312 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab + Statins
Number of subjects: 0
Study 35467312 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe + Statins
Number of subjects: 0
Study 33255787 — intervention group
Group type: EXPERIMENTAL
Intervention: (6S)‐5‐Methyl‐THF‐Na salt (Arcofolin®)
Number of subjects: 24
Study 33255787 — intervention group
Group type: COMPARATOR
Intervention: Folic acid
Number of subjects: 24
Study 33255787 — intervention group
Group type: EXPERIMENTAL
Intervention: (6S)‐5‐Methyl‐THF‐Na and (6S)‐5‐Methyl‐THF‐Ca
Number of subjects: 24
Study 32142563 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte- and platelet-rich fibrin membranes from smokers
Number of subjects: 60
Study 32142563 — intervention group
Group type: COMPARATOR
Intervention: Leukocyte- and platelet-rich fibrin membranes from nonsmokers
Number of subjects: 60
Study 32142563 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced platelet-rich fibrin membranes from smokers
Number of subjects: 60
Study 32142563 — intervention group
Group type: COMPARATOR
Intervention: Advanced platelet-rich fibrin membranes from nonsmokers
Number of subjects: 60
Study 36135341 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-Directed Hemodynamic Therapy (GDHT)
Number of subjects: 70
Study 33477821 — intervention group
Group type: EXPERIMENTAL
Intervention: Alive A. muciniphila
Number of subjects: 0
Study 33477821 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteurized A. muciniphila
Number of subjects: 0
Study 33477821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32065533 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg
Number of subjects: 0
Study 32065533 — intervention group
Group type: COMPARATOR
Intervention: Modelled placebo
Number of subjects: 0
Study 34534172 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.5 ng/ml; n=40)
Number of subjects: 160
Study 34534172 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.7 μg/ml; n=40)
Number of subjects: 160
Study 34534172 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.9% end-tidal; n=39)
Number of subjects: 160
Study 34534172 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine (0.75 μg/ml; n=20)
Number of subjects: 160
Study 34534172 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 160
Study 32800319 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Coronary Intervention (PCI)
Number of subjects: 120
Study 32800319 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 120
Study 33790002 — intervention group
Group type: EXPERIMENTAL
Intervention: sensor-Based Electronic Monitoring for Asthma
Number of subjects: 0
Study 33790002 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33757688 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A (BTX-A) injection into masticatory muscles (masseter and temporalis) 2 weeks prior to surgery
Number of subjects: 20
Study 33757688 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection into masticatory muscles (masseter and temporalis) 2 weeks prior to surgery
Number of subjects: 20
Study 33757688 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A (BTX-A) injection
Number of subjects: 20
Study 33757688 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection
Number of subjects: 20
Study 36093647 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/L CS‐OL‐NPs
Number of subjects: 20
Study 36093647 — intervention group
Group type: COMPARATOR
Intervention: 5% glutaraldehyde solution (GA)
Number of subjects: 20
Study 36093647 — intervention group
Group type: COMPARATOR
Intervention: 1 mg/ml chitosan (CS)
Number of subjects: 20
Study 36093647 — intervention group
Group type: COMPARATOR
Intervention: Deionized Water (DW)
Number of subjects: 20
Study 33956212 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 20
Study 33956212 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 20
Study 33956212 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HIIT and MICT
Number of subjects: 20
Study 32965052 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD-CAM milled bar with long distal extensions (MBDE)
Number of subjects: 40
Study 32965052 — intervention group
Group type: COMPARATOR
Intervention: Retentive anchors (RA)
Number of subjects: 40
Study 35162197 — intervention group
Group type: EXPERIMENTAL
Intervention: UP150 intervention (EG)
Number of subjects: 45
Study 35162197 — intervention group
Group type: COMPARATOR
Intervention: Usual office environment (CG)
Number of subjects: 45
Study 34405565 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil alone
Number of subjects: 20
Study 34405565 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil plus SC BNP
Number of subjects: 20
Study 32915027 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (MORE)
Number of subjects: 95
Study 32915027 — intervention group
Group type: COMPARATOR
Intervention: Support Group (SG)
Number of subjects: 95
Study 36006877 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirituality as a coping mechanism
Number of subjects: 5
Study 36006877 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental duress due to heavy workloads and fear of infection
Number of subjects: 5